Zoledronic acid Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0023 
Minor change in labelling or package leaflet not 
19/04/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0022 
B.II.b.2.c.1 - Change to importer, batch release 
22/06/2022 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0021 
Transfer of Marketing Authorisation 
24/09/2021 
15/11/2021 
SmPC, 
Labelling and 
PL 
IAIN/0020 
A.5.a - Administrative change - Change in the name 
24/03/2021 
22/09/2021 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/09/2020 
22/09/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
N/0018 
Minor change in labelling or package leaflet not 
29/08/2019 
01/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0017/G 
This was an application for a group of variations. 
26/04/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
Page 3/7 
 
 
 
 
 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0016/G 
This was an application for a group of variations. 
10/04/2019 
01/04/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
WS/1370 
This was an application for a variation following a 
06/09/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0014 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
11/09/2017 
28/09/2018 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
R/0013 
Renewal of the marketing authorisation. 
23/03/2017 
24/05/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Zoledronic acid Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0012 
A.5.b - Administrative change - Change in the name 
11/11/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/08/2016 
24/05/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0010 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/12/2015 
22/02/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/11/2015 
22/02/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IAIN/0007 
C.I.8.a - Introduction of or changes to a summary of 
16/07/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/02/2015 
22/02/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
14/08/2014 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/02/2014 
20/02/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/08/2013 
20/02/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
IAIN/0002/G 
This was an application for a group of variations. 
31/05/2013 
20/02/2014 
SmPC, 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2013 
20/02/2014 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Labelling and 
PL 
Page 7/7 
 
 
 
 
 
 
 
 
 
